Tuesday, May 7, 2019
Eidos Therapeutics reports Q1 EPS (32c), consensus (31c)
Cash and cash equivalents totaled $at March 31, compared with $157.1M at December 31, 2018.
https://thefly.com/landingPageNews.php?id=2905239
https://thefly.com/landingPageNews.php?id=2905239
eHealth price target raised to $100 from $87 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for eHealth to $100 from $87 citing the company’s “impressive” five-year outlook at its analyst meeting. The analyst reiterates an Overweight rating on the shares.
Dermira reports Q1 EPS ($1.49), consensus ($1.62)
Reports Q1 revenue $2.45M, consensus $2.64M. As of March 31, 2019, Dermira had cash and investments of $387.8 million and 53.6 million common shares outstanding. Q1 QBREXZA $2.5M vs. $0.3M last year. The company states Q1 “QBREXZA sales were impacted by the company’s launch-related patient financial assistance program designed to broaden patient access, a component of which is being phased out beginning in the second quarter of 2019 as a result of the company having achieved specific objectives for commercial coverage of QBREXZA. ”
https://thefly.com/landingPageNews.php?id=2905113
https://thefly.com/landingPageNews.php?id=2905113
Prothena reports Q2 EPS (52c), consensus (62c)
Reports Q2 revenue $186K, consensus $160K. “We continue to advance our neuroscience pipeline of investigational therapies, and are progressing several programs towards key milestones,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. “We have initiated cell line development of a lead candidate for our tau program under our collaboration with Celgene. Enrollment in our Phase 1 study of PRX004 in ATTR amyloidosis is progressing and we now anticipate that the fourth quarter update on this program will include data from cohorts 1 through 4. Data from Part 1 of the Phase 2 PASADENA study of prasinezumab in Parkinson’s disease, which is being run by Roche, are expected in 2020. We also recently reported results from the Phase 3 VITAL study of NEOD001 in AL amyloidosis and are exploring business development opportunities that could result in further clinical investigation of NEOD001.” The Company is updating its full year 2019 net cash burn from operating and investing activities, and expects it to be $57-65 million, representing a decrease of approximately $7 million, and expects to end the year with approximately $371 million in cash, cash equivalents and restricted cash (midpoint). The Company had planned on initiating cell line development of a lead candidate for an Amyloid beta discovery program this year but will not be making additional investments in this program at this time based on the recent discontinuation of Biogen’s aducanumab program. The updated estimated full year 2019 cash burn from operating and investing activities is primarily driven by an updated estimated net loss of $83-94 million, which includes an estimated $24 million of non-cash shared-based compensation expense.
https://thefly.com/landingPageNews.php?id=2905115
https://thefly.com/landingPageNews.php?id=2905115
Subscribe to:
Posts (Atom)